Prophylactic measures in patients without and with VTE during induction
| . | All patients (n = 784) . | No thrombosis during induction (n = 706) . | Thrombosis during induction (n = 78) . | P . |
|---|---|---|---|---|
| L-ASP injections, n (IQR) | 8 (5-8) | 8 (5-8) | 6 (3-8) | <.001 |
| AT nadir, n (IQR) | 51 (45-58) | 51 (45-58) | 51 (44-62) | .66 |
| AT prophylaxis, n (%) | 684 (87) | 620 (88) | 64 (82) | .05 |
| FFP prophylaxis, n (%) | 76 (10) | 68 (10) | 8 (10) | .82 |
| Fibrinogen prophylaxis, n (%) | 70 (9) | 58 (8) | 12 (15) | .02 |
| Heparin prophylaxis, n (%) | ||||
| No | 177 (23) | 164 (23) | 13 (17) | .04 |
| Yes | 485 (62) | 421 (60) | 64 (82) | — |
| Missing data | 122 (15) | 121 (17) | 1 (1) | — |
| . | All patients (n = 784) . | No thrombosis during induction (n = 706) . | Thrombosis during induction (n = 78) . | P . |
|---|---|---|---|---|
| L-ASP injections, n (IQR) | 8 (5-8) | 8 (5-8) | 6 (3-8) | <.001 |
| AT nadir, n (IQR) | 51 (45-58) | 51 (45-58) | 51 (44-62) | .66 |
| AT prophylaxis, n (%) | 684 (87) | 620 (88) | 64 (82) | .05 |
| FFP prophylaxis, n (%) | 76 (10) | 68 (10) | 8 (10) | .82 |
| Fibrinogen prophylaxis, n (%) | 70 (9) | 58 (8) | 12 (15) | .02 |
| Heparin prophylaxis, n (%) | ||||
| No | 177 (23) | 164 (23) | 13 (17) | .04 |
| Yes | 485 (62) | 421 (60) | 64 (82) | — |
| Missing data | 122 (15) | 121 (17) | 1 (1) | — |